China's Biotech Boom Reshapes Global Drug Deals and Medical Innovation

Billions in Drug Deals Mark China's Growing Reach

Chinese biotechnology companies are moving into the centre of global drug development, with international licensing deals bringing money and attention to an industry once known mainly for generic medicines. China accounted for nearly 32% of global out-licensing deal value in 2024, up from 21% in previous years. The number of licensing deals involving China rose from 55 in 2015 to 213 in 2024, while their total value increased from $3.1 billion to $57.1 billion.

By August 22, 2025, agreements involving Pfizer, Bristol Myers Squibb, BioNTech, AstraZeneca and Merck illustrated the scale of that change. Pfizer agreed to pay 3SBio $1.25 billion upfront for rights to a promising cancer drug, under an agreement potentially worth $6.05 billion. Other transactions covered cancer immunotherapies, treatments using modified immune cells and technologies that help immune cells attack tumours.

China's companies are increasingly supplying medicines that Western pharmaceutical groups need to replace revenue from older products as patent protection approaches its end. For Chinese developers, international partnerships provide funding in a period of weaker private investment and difficult equity markets. For patients, the partnerships create routes through which treatments developed in China can reach clinical trials and markets overseas.

Premier Li Qiang has called for stronger policy backing for biotechnology, stressing original innovation and faster breakthroughs in core technologies. His remarks, reported by Xinhua News Agency, place the sector within China's priorities for public health and economic growth.

The transformation is changing the direction in which medical innovation travels. China is moving beyond supplying inexpensive medicines and pharmaceutical ingredients toward developing treatments that multinational companies want to bring into their own research programmes. That shift is challenging the traditional dominance of the United States and Europe in drug discovery and development.

Faster Reviews, Public Support and Returning Talent

China's National Medical Products Administration (NMPA) began overhauling drug approval procedures in 2015. The reforms brought standards closer to international practice and shortened review times. Applications to begin testing experimental medicines in people, known as investigational new drug applications, once took nearly two years to process. They now take a few months.

China joined the International Council for Harmonisation in 2017, bringing it more closely into the international system for aligning drug development and regulatory standards. That integration has made Chinese clinical data more acceptable to Western regulators and helped companies prepare medicines for development beyond their domestic market.

Government funding, infrastructure and incentives have supported the expansion. Biotechnology has been prioritised in national development plans, while drug discovery using artificial intelligence is described as a formal priority in China's Five-Year Plan for 2025.

Chinese companies also benefit from a large pool of professionals trained in science, technology, engineering and mathematics. Many have returned from overseas after working at leading Western pharmaceutical companies, bringing experience in research and drug development into Chinese businesses.

Clinical trials and research and development cost less in China than in the West. Combined with artificial intelligence, automation and advanced manufacturing, those advantages allow companies to advance experimental medicines more quickly and efficiently, sometimes outpacing traditional development methods. The industry's focus now extends beyond generic drugs and active pharmaceutical ingredients, the substances that give medicines their therapeutic effect, into oncology, immunology and metabolic diseases.

Why Global Pharma Is Buying Chinese Innovation

Large pharmaceutical companies face a recurring problem: successful medicines eventually lose patent protection, opening the market to competition. This pressure, often called a patent cliff, makes new products essential. Merck's Keytruda and Novo Nordisk's Ozempic are among the blockbuster medicines whose approaching patent expirations are encouraging companies to replenish their development pipelines.

A Nature analysis put the share of major pharmaceutical companies' innovative pipeline assets licensed from China in 2024 at 31%. A pipeline is the collection of experimental medicines a company is developing, from initial research through clinical testing.

The appeal combines speed, cost and access to increasingly sophisticated science. Chinese companies can conduct trials faster and at lower expense, bringing promising candidates to potential partners earlier. Licensing those candidates, or accessing Chinese artificial intelligence platforms, can be more affordable than developing therapies from the beginning in the West.

China's strength is particularly visible in cancer research. The country accounts for 39% of global oncology clinical trials, placing it first worldwide. Its developers are also prominent in complex biologic medicines, including antibody-drug conjugates and bispecific antibodies.

An antibody-drug conjugate links an antibody that recognises a target on a cancer cell to a drug intended to kill that cell. A bispecific antibody can bind to two targets. These approaches are central to several of the partnerships drawing international attention to Chinese research.

The global prescription drug market is projected to grow from $1.23 trillion in 2024 to $2.45 trillion by 2032, almost doubling. Pharmaceutical companies seeking a share of that growth are increasingly treating Chinese innovation as a source of future products.

The Agreements Behind the Shift

Pfizer's agreement with 3SBio combines a large initial payment with the possibility of further payments. Its $1.25 billion upfront commitment sits within a deal that could reach $6.05 billion. The larger figure is the potential total, while the upfront amount is the money committed at the beginning.

BioNTech and Bristol Myers Squibb have a $1.5 billion deal involving a therapy acquired from Chinese startup Biotheus. AstraZeneca's $1 billion partnership with Gracell Biotechnologies centres on CAR-T cell therapy technology. CAR-T treatments use immune cells modified to recognise and attack cancer.

Merck's $700 million agreement with Curon Biopharmaceutical concerns T-cell engager technology. These treatments are designed to bring T cells, a type of immune cell, into contact with cancer cells so the immune system can attack them.

The agreements show how global pharmaceutical groups are looking to China for different kinds of innovation, rather than a single product category. They also illustrate why biotechnology deal values can be much larger than the cash paid immediately: payments may be spread across development, regulatory and commercial milestones.

An industry analyst, whose name was not given in the January 2025 BioSpace account, described the direction of the trend:

These trends indicate that China's influence on the global pharma industry is likely to deepen in the coming years.

International Deals Become a Financial Lifeline

Chinese biotechnology companies have traditionally used out-licensing agreements to fund expensive and risky drug development. Under this model, a company grants a partner rights to develop or sell a medicine in agreed markets. Chinese developers often make such deals after completing early trials at home, leaving global partners to take the candidates further internationally.

Upfront payments, near-term milestone payments and equity investments in deals taking Chinese assets to Western partners reached a combined $8.4 billion in 2024. China-based biotechnology companies raised $4.2 billion in the private market that year. The money from those international deal components was therefore twice the private fundraising total.

Licensing revenue also exceeded total equity fundraising for the sector in 2024. That matters because equity fundraising requires companies to sell ownership stakes, while licensing brings in money through rights to particular medicines. International deals have become a vital source of revenue and outside recognition for Chinese developers.

China's largely government-funded healthcare system and national insurance schemes keep domestic drug prices low. Companies developing costly new therapies therefore have strong reasons to seek additional revenue abroad.

Private investment in China's biotechnology sector fell to just 28% of its 2021 level in 2024. Tighter rules for initial public offerings, when companies first sell shares to public investors, and sluggish equity markets have made global partnerships more important for startups trying to finance their next trials.

BeiGene and Innovent Biologics are showing signs of financial stabilisation, with profits and increased revenues following years of market downturns. Across the industry, however, only a minority of companies secure major international partnerships. Competition for those agreements is intensifying, contributing to a restructuring around drugs that can compete globally.

New Companies Offer Another Route Overseas

Chinese developers are experimenting with the NewCo model, in which an overseas company is created to hold particular experimental medicines. The new business raises international capital and manages clinical development, while the Chinese developer keeps an equity stake and influence over decisions.

At least 13 such transactions had been completed by Chinese companies by the first quarter of 2025, with a cumulative value exceeding $10 billion, according to China Daily. The model is expected to become a major strategy for taking Chinese innovative medicines overseas.

A traditional licensing agreement transfers specified rights to an established partner. A NewCo instead places the assets in a separate business that can attract its own investors. For Chinese developers, the attraction is access to global funding while retaining a continuing stake in the medicines' development.

These structures can move candidates at an early stage into international development more quickly and give their original developers several potential sources of income. They also allow Chinese companies to keep more influence over their assets as they expand beyond the domestic market.

Cancer Research Drives the Innovation Push

Chinese biotechnology firms are moving from medicines commonly described as "me-too" drugs, or copies of existing therapies, toward treatments intended to be first-in-class or best-in-class. A first-in-class medicine introduces a new therapeutic approach. A best-in-class medicine aims to perform better than others in its category.

Much of the current work focuses on targets already supported by research, including PD-1/VEGF bispecific antibodies for cancer. These medicines combine two approaches: helping the immune system respond to cancer and targeting signals involved in the blood supply that tumours use. Chinese companies are also seeking entirely new ways to treat disease.

Akeso Biopharma's ivonescimab outperformed Merck's Keytruda in clinical trials. That result helped ignite a global race for Chinese-developed PD-1/VEGF candidates, encouraged a rush of multinational partnerships and drove intense interest in capital markets.

Industry insiders have described the rise in global attention as a "DeepSeek moment", meaning a point at which Chinese innovation developed at home gains international relevance. In biotechnology, the phrase captures the growing interest in research that pharmaceutical companies elsewhere want to acquire or develop jointly.

China developed more than 1,250 new drugs in 2024, exceeding Europe's output and approaching the United States' 1,440. Together with its leading share of oncology trials, that activity helps explain the changing perception of China from a supplier of inexpensive generics to a centre for advanced medical research.

Artificial Intelligence Adds Speed and Investment

XtalPi and Insilico Medicine are among the startups using artificial intelligence and automation in drug discovery. Their work has attracted major deals involving companies such as AstraZeneca, Pfizer and Sanofi. These tools help researchers search for promising candidates and accelerate parts of the development process.

China's large patient population and national health insurance system provide extensive potential training datasets for artificial intelligence models. Its pool of chemistry specialists and artificial intelligence engineers supports the businesses trying to turn those tools into useful medicines.

Tencent, Baidu, Alibaba and ByteDance are investing in biotechnology startups, bringing technology company capital into the sector. Their participation adds to the government support and pharmaceutical partnerships already helping finance research.

Artificial intelligence sits alongside automation and advanced manufacturing in China's effort to shorten development schedules. The commercial opportunity is tied to the same needs driving licensing deals: pharmaceutical companies want promising new medicines while facing rising research costs and pressure to replace ageing products.

A Breast Cancer Partnership Shows the Wider Reach

Shanghai Henlius Biotech has announced a strategic collaboration with GeneQuantum Healthcare and Envision Pharma, based in the United Kingdom, to develop and commercialise GQ1005. The medicine is an innovative antibody-drug conjugate targeting HER2 for breast cancer.

HER2 is the target used to direct this treatment toward relevant cancer cells. Like other antibody-drug conjugates, GQ1005 combines an antibody with a cancer drug, linking recognition of a target to delivery of treatment.

The agreement covers China and certain overseas markets. It illustrates how partnerships can connect development at home with commercial ambitions abroad, expanding the potential reach of Chinese therapies while reinforcing the country's position in oncology.

Global Approval Still Requires Global Evidence

Chinese clinical data is becoming more acceptable to Western regulators, but concerns about trial diversity and data quality remain. Developers seeking approval abroad must address whether their evidence meets the requirements of the markets where they want to sell a medicine.

Eli Lilly's unsuccessful attempt to bring Tyvyt, a cancer drug developed in China, to the United States shows the practical consequences. The effort failed because of a lack of global trial data. A medicine intended for international use needs a development programme that answers the questions regulators in those markets ask.

More Chinese companies are launching clinical trials across multiple regions as their businesses become more international. The United States Food and Drug Administration and the European Medicines Agency are also fast-tracking more Chinese drug approvals, while multinational companies are investing heavily in Chinese innovation.

The regulatory gains sit alongside continuing work on international alignment and intellectual property protection. For patients, commercial agreements are one stage in a longer process: candidates still need the clinical development and regulatory decisions required to become available medicines.

Political Pressure and the Dates Behind the Boom

United States policymakers have introduced measures such as the BIOSECURE Act targeting certain Chinese firms, creating uncertainty for future collaboration. Licensing activity has continued despite that pressure, with American companies still obtaining rights to Chinese medicines.

Geopolitical tensions, funding constraints and stronger competition are shaping which Chinese companies can expand abroad. Their challenge is to keep developing competitive medicines, secure partners and navigate international markets while maintaining the pace of innovation.

The transformation has unfolded through regulatory changes and an expanding deal market over a decade:

• 2015: The NMPA began overhauling drug approval procedures. China-related licensing deals numbered 55 and were worth $3.1 billion.
• 2017: China joined the International Council for Harmonisation, deepening its integration into global drug regulation.
• 2021: Private investment reached the comparison level against which 2024 funding would fall to 28%.
• 2024: China-related licensing deals reached 213, worth $57.1 billion. International deal payments and equity investments totalled $8.4 billion, compared with $4.2 billion raised privately.
• January 2025: The industry analyst quoted in BioSpace described China's influence on global pharmaceuticals as likely to deepen.
• First quarter of 2025: Chinese companies had completed at least 13 NewCo transactions with a cumulative value above $10 billion.
• August 22, 2025: Licensing, international trials and new partnership structures were central to the industry's expansion overseas.

Western pharmaceutical companies' need for new products and Chinese developers' need for capital are bringing the two sides closer together. Industry expectations point to deeper Chinese influence as companies seek innovation at manageable costs. Continued international expansion depends on the same concrete tasks already facing developers: financing research, producing clinical evidence and taking medicines through approval.

Key Points

• China-related licensing deals rose from 55 worth $3.1 billion in 2015 to 213 worth $57.1 billion in 2024.
• Chinese biotechnology accounted for nearly 32% of global out-licensing deal value in 2024, up from 21% in previous years.
• Pfizer, Bristol Myers Squibb, BioNTech, AstraZeneca and Merck are among the companies pursuing Chinese-developed therapies.
• International deal payments and equity investments reached $8.4 billion in 2024, twice the $4.2 billion raised in China's private biotechnology market.
• China accounts for 39% of global oncology clinical trials and developed more than 1,250 new drugs in 2024, compared with 1,440 in the United States.
• At least 13 NewCo transactions worth more than $10 billion had been completed by the first quarter of 2025.
• Regulatory requirements, weaker funding, competition and geopolitical tensions remain central challenges for expansion abroad.